NCT01953341View on ClinicalTrials.gov

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

November 30, 2014

Conditions
Migraine
Interventions
DRUG

AMG 333

Oral administration available in varying dose strength.

DRUG

Placebo

Placebo containing no active drug

Trial Locations (1)

84106

Research Site, Salt Lake City

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01953341 - Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines | Biotech Hunter | Biotech Hunter